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A B S T R A C T
Background
Deep vein thrombosis (DVT) occurs when a blood clot blocks blood flow through a vein, which can occur after surgery, after trauma,
or when a person has been immobile for a long time. Clots can dislodge and block blood flow to the lungs (pulmonary embolism
(PE)), causing death. DVT and PE are known by the term venous thromboembolism (VTE). Heparin (in the form of unfractionated
heparin (UFH)) is a blood-thinning drug used during the first three to five days of DVT treatment. Low molecular weight heparins
(LMWHs) allow people with DVT to receive their initial treatment at home instead of in hospital. This is an update of a review first
published in 2001 and updated in 2007.
Objectives
To compare the incidence and complications of venous thromboembolism (VTE) in patients treated at home versus patients treated
with standard in-patient hospital regimens. Secondary objectives included assessment of patient satisfaction and cost-effectiveness of
treatment.
Search methods
For this update, the Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register (last searched 16
March 2017), the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2), and trials registries. We also checked
the reference lists of relevant publications.
Selection criteria
Randomised controlled trials (RCTs) examining home versus hospital treatment for DVT, in which DVT was clinically confirmed and
was treated with LMWHs or UFH.
Data collection and analysis
One review author selected material for inclusion, and another reviewed the selection of trials. Two review authors independently
extracted data and assessed included studies for risk of bias. Primary outcomes included combined VTE events (PE and recurrent DVT),
gangrene, heparin complications, and death. Secondary outcomes were patient satisfaction and cost implications. We performed meta-
analysis using fixed-effect models with risk ratios (RRs) and 95% confidence intervals (CIs) for dichotomous data.
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Main results
We included in this review seven RCTs involving 1839 randomised participants with comparable treatment arms. All seven had
fundamental problems including high exclusion rates, partial hospital treatment of many in the home treatment arms, and comparison
of UFH in hospital versus LMWH at home. These trials showed that patients treated at home with LMWH were less likely to have
recurrence of VTE events than those given hospital treatment with UFH or LMWH (fixed-effect risk ratio (RR) 0.58, 95% confidence
interval (CI) 0.39 to 0.86; 6 studies; 1708 participants; P = 0.007; low-quality evidence). No clear difference was seen between groups
for major bleeding (RR 0.67, 95% CI 0.33 to 1.36; 6 studies; 1708 participants; P = 0.27; low-quality evidence), minor bleeding (RR
1.29, 95% CI 0.94 to 1.78; 6 studies; 1708 participants; P = 0.11; low-quality evidence), or mortality (RR 0.69, 95% CI 0.44 to
1.09; 6 studies; 1708 participants; P = 0.11; low-quality evidence). The included studies reported no cases of venous gangrene. We
could not combine patient satisfaction and quality of life outcomes in meta-analysis owing to heterogeneity of reporting, but two of
three studies found evidence that home treatment led to greater improvement in quality of life compared with in-patient treatment
at some point during follow-up, and the third study reported that a large number of participants chose to switch from in-patient care
to home-based care for social and personal reasons, suggesting it is the patient’s preferred option (very low-quality evidence). None of
the studies included in this review carried out a full cost-effectiveness analysis. However, a small randomised economic evaluation of
the two alternative treatment settings involving 131 participants found that direct costs were higher for those in the in-patient group.
These findings were supported by three other studies that reported on their costs (very low-quality evidence).
Quality of evidence for data from meta-analyses was low to very low. This was due to risk of bias, as many of the included studies used
unclear randomisation techniques, and blinding was a concern for many. Also, indirectness was a concern, as most studies included a
large number of participants randomised to the home (LMWH) treatment group who were treated in hospital for some or all of the
treatment period. A further issue for some outcomes was heterogeneity that was evident in measurement and reporting of outcomes.
Authors’ conclusions
Low-quality evidence suggests that patients treated at home with LMWH are less likely to have recurrence of VTE than those treated in
hospital. However, data show no clear differences in major or minor bleeding, nor in mortality (low-quality evidence), indicating that
home treatment is no worse than in-patient treatment for these outcomes. Because most healthcare systems are moving towards more
LMWH usage in the home setting it is unlikely that additional large trials will be undertaken to compare these treatments. Therefore,
home treatment is likely to become the norm, and further research will be directed towards resolving practical issues by devising local
guidelines that include clinical prediction rules, developing biomarkers and imaging that can be used to tailor therapy to disease severity,
and providing training for community healthcare workers who administer treatment and monitor treatment progress.
P L A I N L A N G U A G E S U M M A R Y
Home versus in-patient treatment for deep vein blood clots
Background
Deep vein thrombosis (DVT) occurs when a blood clot blocks the flow of blood through a vein, generally in the legs. This can happen
after surgery, after trauma, when a person is immobile for a long time, or for no obvious reason. Clots can dislodge and block blood flow
to the lungs (pulmonary embolism (PE)), which can be fatal. DVT and PE are known as venous thromboembolism (VTE). Heparin
is a blood-thinning drug that is used to treat DVT during the first three to five days. Unfractionated heparin (UFH) is administered
intravenously in hospital with laboratory monitoring. Low molecular weight heparins (LMWHs) are given by subcutaneous injection
once a day and can be given at home. Oral anticoagulants are then continued for three to six months. After recovery from the acute
episode, people may develop post-thrombotic syndrome with leg swelling, varicose veins, and ulceration.
Study characteristics and key results
Seven randomised controlled trials involving 1839 patients with clinically confirmed DVT compared home (LMWH) versus hospital
(unfractionated heparin, or LMWH in one trial) treatment. Trials had limitations, including high exclusion rates and designs that did
not take into account short hospital stays for any of the people treated at home to allow fair comparison of heparin in hospital with
LMWH at home.
Trials showed that patients treated at home with LMWH had less recurrence of VTE than hospital-treated patients. The review showed
no clear differences between treatment groups for major bleeding, minor bleeding, or death. No study reported venous gangrene. We
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could not pool information on patient satisfaction and quality of life, as studies had different ways of reporting these, but two of the
three studies reporting on quality of life provided evidence that home treatment led to greater improvement in quality of life compared
with in-patient treatment, at some point during follow-up. The third study reported that a large number of participants chose to switch
from in-patient care to home-based care for social and personal reasons, indicating that home treatment was better accepted than in-
patient treatment. Studies that looked at cost found that cost of home management was lower per incident of treatment.
Quality of the evidence
Overall, the quality of evidence of the available data was low to very low owing to risk of bias, indirectness, and differences in measuring
and reporting of outcomes. Risk of bias is a concern, as many of the included studies did not fully explain how they randomised
and allocated participants to treatments, and blinding techniques described were not clear. Full blinding would be difficult if not
impossible for these types of treatments (home vs hospital), but some techniques could be put in place such as using the same treatment
medications or blinding those who measure outcomes. Another concern of reviewers was that in some studies, participants randomised
to home treatment actually ended up being treated in hospital but remained in their assigned treatment for the analysis (this is known
as indirectness). This makes it hard to determine whether trial results actually can be used to answer the question of whether home
versus hospital treatment for DVT is superior. A further concern regarding a few of outcomes is variation in the way outcomes were
measured and reported.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
How does treatment of DVT at home compare with treatment in hospital?
Patient or population: people with diagnosed DVT
Setting: hospital and home
Intervention: t reatment of DVT at home with LMWHa
Comparison: t reatment of DVT in hospital with UFH or LMWHb
Outcomes No. of participants
(studies)
Follow-up
Quality of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects* (95% CI) Comments
Risk with treatment of
DVT in hospital
Risk difference with
treatment of DVT at
home
Recurrence of VTE
Follow-up: range 3
months to 12 months
1708
(6 RCTs)
⊕⊕©©
LOWc,d
RR 0.58
(0.39 to 0.86)
Study populat ion
74 per 1000 31 fewer per 1000
(45 fewer to 10 fewer)
Venous gangrene See comment. This outcome was not
reported by any of the
included studies
Major bleeding
Follow-up: range 14
days to 12 months
1708
(6 RCTs)
⊕⊕©©
LOWc,d
RR 0.67
(0.33 to 1.36)
Study populat ion
21 per 1000 7 fewer per 1000
(14 fewer to 8 more)
Minor bleeding
Follow-up: range 14
days to 12 months
1708
(6 RCTs)
⊕⊕©©
LOWc,d
RR 1.29
(0.94 to 1.78)
Study populat ion
72 per 1000 21 more per 1000
(4 fewer to 56 more)
Death
fFollow-up: range 3
months to 12 months
1708
(6 RCTs)
⊕⊕©©
LOWc,d
RR 0.69
(0.44 to 1.09)
Study populat ion
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49 per 1000 15 fewer per 1000
(28 fewer to 4 more)
Patient satisfaction/
Quality of life
Follow-up: range 7 days
to 6 months
1031
(3 RCTs)
⊕©©©
VERY LOWc,d,e
- See comment. Two studies reported
greater improvement in
QoL among part ici-
pants treated at home
than among those re-
ceiving in-pat ient treat-
ment; the third study
reported that a large
number of part icipants
chose to switch f rom in-
pat ient care to home-
based care, suggest ing
this may be pat ients’
preferred opt ion
Cost-effectivenessf
Follow-up: range 10
days to 6 months
834
(4 RCTs)
⊕©©©
VERY LOWc,d,e
- See comment. One study carried out a
randomised economic
evaluat ion and reported
that total direct costs
were higher for par-
t icipants in the in-pa-
t ient strategy group (i.
e. Swedish Crown (SEK)
16,400 per part icipant
(Euro (EUR) 1899) com-
pared with SEK 12,100
per part icipant (EUR
1405)) than for those in
the out-pat ient (home)
strategy group (P < 0.
0010). This was sup-
ported by 3 other stud-
ies that reported on
costs
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*We calculated the assumed risk of the hospital t reatment group f rom the average risk in the hospital t reatment group (i.e. the number of part icipants with events divided by
the total number of part icipants in the hospital t reatment group included in the meta-analysis). The risk in the intervention group (and its 95% conf idence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; DVT: deep vein thrombosis; LMWH: low molecular weight heparin; RR: risk rat io; UFH: unf ract ionated heparin; VTE: venous thromboembolism
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHome treatment refers to treatment for DVT with an LMWH that occurs outside of a hospital or in-pat ient sett ing and can
include the medicat ion being administered by the part icipant or by a caregiver.
bHospital t reatment refers to treatment for DVT with an LMWH or a UFH in a hospital or in-pat ient sett ing that is administered
by care staf f .
cDowngraded one level owing to risk of bias f rom unclear randomisat ion techniques and blinding measures in most included
studies.
dDowngraded one level owing to indirectness because most of the included studies had few part icipants actually treated at
home with an LMWH, and many were treated in hospital.
eDowngraded one level owing to heterogeneity because the included studies used dif ferent methods and t ime points for
gathering information on this outcome.
fWe are report ing on the cost-ef fect iveness analysis reported in the included studies. We have not carried out an economic
analysis ourselves.
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B A C K G R O U N D
Description of the condition
Deep vein thrombosis (DVT) is a frequent disorder in western
medical practice, affecting one to two per thousand of the adult
population annually. DVT occurs in conjunction with malig-
nancy, after surgery, and after trauma and immobilisation, and can
occur spontaneously. It manifests in the acute stage with leg symp-
toms and, in a small minority, with potentially fatal pulmonary
embolism (PE). Venous thromboembolism (VTE) is a term that
refers to both DVT and PE. After recovery from the acute episode,
people may develop post-thrombotic syndrome with leg swelling,
varicosis, and ulceration. Gold standard techniques for diagnosing
DVT include ascending venography and duplex ultrasound scan-
ning. Deep vein thrombosis is most commonly managed by anti-
coagulants to prevent spread of the clot proximally and to allow it
to become adherent or undergo fibrinolysis, thus reducing the risk
of PE. Currently used anticoagulant treatments include unfrac-
tionated and low molecular weight heparin (UFH and LMWH,
respectively), as well as vitamin K antagonists (VKAs), primarily
warfarin, and direct oral anticoagulants (DOACs) (NICE 2012;
Robertson 2015; van Es 2014).
Description of the intervention
In the hospitalised patient, UFH is usually administered intra-
venously, with laboratory monitoring for about five days, overlap-
ping with oral anticoagulants, which are continued for three to six
months. LMWH is administered daily by subcutaneous injection;
it can be delivered at home without the need for continuous lab-
oratory monitoring and may be followed by an oral anticoagulant
regimen.
Why it is important to do this review
Development of LMWHs has resulted in many trials investigat-
ing their efficaciousness and safety, as compared with UFH. These
studies show that LMWH is at least as effective as UFH; some
meta-analyses and reviews show that LMWH is more effective
and safer than UFH (Erkens 2010; Leizorovicz 1994; Lensing
1995). Because LMWH is given subcutaneously once per day and
requires no laboratory monitoring, it is possible to treat people
with LMWH at home. Although LMWH has been available since
1976, home treatment has not been investigated further since the
time it was first reported in 1988 (Bakker 1988). Rigorous evalua-
tion of home versus in-patient care is required to inform policy on
alternative strategies for treating patients with DVT. Home treat-
ment of DVT offers potential cost savings and improved social ac-
ceptability for the patients. This review aims to update the review
that was first published in 2001 and updated in 2007 (Othieno
2007).
O B J E C T I V E S
To compare the incidence and complications of venous throm-
boembolism (VTE) in patients treated at home versus patients
treated with standard in-patient hospital regimens. Secondary ob-
jectives included assessment of patient satisfaction and cost-effec-
tiveness of treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) in which partic-
ipants were randomised to home or in-patient treatment. Exclu-
sion criteria before randomisation had to be stated and the trial au-
thor’s policy regarding protocol violations and withdrawals known
(i.e. intention-to-treat basis).
Types of participants
We included people with proven VTE who had no contraindi-
cation to heparin therapy, and whose home circumstances were
adequate. Participants had to present with objective evidence of
DVT such as duplex scanning and/or venography.
Types of interventions
We included studies that compared home versus hospital manage-
ment with LMWH (which can be used in either setting) or UFH
(which is used in hospital only). Trials involving a placebo group
are not ethically acceptable.
Types of outcome measures
Primary outcomes
• Recurrence of VTE: PE or recurrence of DVT (depending
on length of follow-up)
• Venous gangrene
• Heparin complications: major and minor bleeding (the
former defined as bleeding within the abdomen, cranium, or eye,
or requiring transfusion, or causing a fall in haemoglobin ≥ 2 g/
dL)
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• Death
Ideally, evidence of PE is derived from lung scans, spiral computed
tomography (CT), or pulmonary angiography, but as these meth-
ods were not likely to be widely available, we considered X-rays,
electrocardiograms (ECGs), and strong clinical signs acceptable.
In the event of death, postmortem evidence was desirable.
Secondary outcomes
• Patient satisfaction and quality of life
• Cost-effectiveness of treatment (as reported by individual
studies)
We will also report on other outcomes of interest (i.e. post-throm-
botic syndrome or length of stay in hospital), when reported by
individual studies.
Search methods for identification of studies
Electronic searches
For this update, the Cochrane Vascular Information Specialist
(CIS) searched the following databases for relevant trials.
• Cochrane Vascular Specialised Register (16 March 2017).
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 2) via the Cochrane Register of Studies
Online.
See Appendix 1 for details of the search strategy used for CEN-
TRAL.
The Cochrane Vascular Specialised Register is maintained by the
CIS and is constructed from weekly electronic searches of MED-
LINE Ovid, Embase Ovid, the Cumulative Index to Nursing and
Allied Health Literature (CINAHL), and the Allied and Comple-
mentary Medicine Database (AMED), as well as through hand-
searching of relevant journals. The full list of databases, jour-
nals, and conference proceedings searched, as well as the search
strategies used, are described in the Specialised Register section
of the Cochrane Vascular module in the Cochrane Library (
www.cochranelibrary.com).
In addition, the CIS searched the following trial databases for
details of ongoing and unpublished studies (16 March 2017). See
Appendix 2.
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) Search Portal (apps.who.int/
trialsearch).
• ClinicalTrials.gov (clinicaltrials.gov).
• International Standard Randomised Controlled Trial
Number (ISRCTN) Registry (www.isrctn.com).
Searching other resources
We identified additional articles by reviewing the references of
relevant papers identified by the initial search.
Data collection and analysis
Selection of studies
For this update, three review authors (RO, EO,RF) independently
selected trials. Final selection of articles was agreed upon through
discussion and consensus.
Data extraction and management
Two review authors (RO, EO) independently extracted data from
existing and newly included trials using the criteria designated by
Cochrane Vascular. For some references, we sought clarification
from trial authors. Two review authors (RO, EO) performed data
entry.
Assessment of risk of bias in included studies
Two review authors (RO, EO) independently assessed the risk of
bias of all included studies using Cochrane’s ’Risk of bias’ tool,
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We rated studies as having ’low risk
of bias’ (plausible bias that is unlikely to seriously alter the results);
’high risk of bias’ (plausible bias that seriously weakens confidence
in the results); or ’unclear risk of bias’ (plausible bias that raises
some doubt about results). We assessed included RCTs against the
six domains listed below.
• Sequence generation: Was the allocation sequence
adequately described?
• Allocation concealment: Was allocation adequately
concealed?
• Blinding of participants, personnel, and outcome assessors:
Was knowledge of the allocation intervention adequately
prevented during the study?
• Incomplete outcome data: Were incomplete outcome data
adequately addressed?
• Selective outcome reporting: Are reports of the study free of
the suggestion of selective outcome reporting?
• Other sources of bias: Did the study appear to be free of
other problems that could put it at high risk of bias?
Measures of treatment effect
Two review authors (RO, EO) performed the data analysis ac-
cording to the statistical guidelines provided for review authors by
Cochrane Vascular. When data were sufficient, we calculated risk
ratios (RRs) with 95% confidence intervals (CIs) using Review
Manager software (RevMan 2014).
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Unit of analysis issues
None of the included studies applied non-standard designs, such
as cross-over trials or cluster-randomised trials. Therefore wemade
no adjustments for measurement effects. The individual partici-
pant was the unit of analysis.
Dealing with missing data
We aimed to conduct a complete-case analysis in this Cochrane
Review, such that we included in the analysis all participants with
a recorded outcome. We analysed data on an intention-to-treat
basis as far as possible. When data were missing, wemade attempts
to obtain them from the original investigators. When they were
unobtainable, we analysed only available data, based on the nu-
merator and the denominator reported in study results or calcula-
ble from reported percentages.
Assessment of heterogeneity
We examined heterogeneity between trials by visually examining
forest plots to judge whether any differences between studies in
direction or size of the treatment effect were apparent. We also
considered I² andTau² statistics and the P value of the Chi² test for
heterogeneity. If we identifiedheterogeneity among trials (i.e. if the
value of I² was greater than 30%, and the value of Tau² was greater
than zero or the P value of theChi² test for heterogeneity was lower
than 0.1), we planned to explore heterogeneity by performing
prespecified sensitivity analysis as described below.
Assessment of reporting biases
In view of the difficulty involved in detecting and correcting for
publication bias and other reporting biases, we aimed to minimise
their potential impact by ensuring a comprehensive search for
eligible studies and by staying alert for duplication of data. We
planned to use a funnel plot to assess the possibility of small-study
effects (a tendency for estimates of the intervention effect to be
more beneficial in smaller studies) for the primary reviewoutcomes
when we included 10 or more studies in meta-analyses (Higgins
2011). We intended to cautiously consider visible asymmetry in
the funnel plot as a possible indication of publication bias.
Data synthesis
We carried out statistical analysis using Review Manager software
(RevMan 2014). We used a fixed-effect meta-analysis for com-
bining data when it was reasonable to assume that studies were
estimating the same underlying treatment effect (i.e. when trials
were examining the same intervention, and when we judged that
trial populations and methods were sufficiently similar).
We planned to use random-effects meta-analysis if clinical hetero-
geneity was sufficient to expect that underlying treatment effects
differed between trials, or if we detected substantial statistical het-
erogeneity.
Subgroup analysis and investigation of heterogeneity
If identified, we planned to explore any possible evidence of het-
erogeneity within meta-analyses by performing subgroup analysis.
We planned to perform no other subgroup analyses.
Sensitivity analysis
We performed sensitivity analyses by excluding studies that we
judged to be at high risk of bias to determine effects on overall
findings. We also performed sensitivity analysis if a single study
carried most of the weight when we included three or more stud-
ies in an analysis. We performed additional sensitivity analysis
to determine the robustness of findings that included data from
Koopman 1996, Levine 1996, and Ramacciotti 2004, when we
found that participants randomised to LMWH were treated only
at home, as determined by a clinician, but were not specifically
assigned to home treatment.
’Summary of findings’
We presented the main findings of the review concerning quality
of evidence, magnitude of effect of interventions examined, and
the sum of available data for all outcomes of this review (Types
of outcome measures) in a ’Summary of findings’ table, accord-
ing to GRADE principles, as described by Higgins 2011 and
Atkins 2004. We evaluated evidence on the basis of risk of bias
of the included studies, inconsistency, indirectness, and impreci-
sion of data, as well as publication bias. We used GRADEprofiler
(GRADEpro) software to assist in preparation of the ’Summary
of findings’ table (GRADEProGDT 2015), and we used the Ryan
2016 publication to prepare GRADE ratings.
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
In total, seven studies with a total of 1839 participants were eligi-
ble for inclusion in this review (Bäckman 2004; Boccalon 2000;
Chong 2005; Daskalopoulos 2005; Koopman 1996; Levine 1996;
Ramacciotti 2004). We identified one new study for inclusion in
this review update (Bäckman 2004). This study had previously
been excluded on the grounds that it did not assess any of the
primary outcomes, but after further assessment, we decided we
should include it, as the study did report on economic data.
Three large trials randomised 298 (150 home and 148 hospital),
400 (202 home and 198 hospital), and 500 participants (247
home and 253 hospital), respectively (Chong 2005; Koopman
1996; Levine 1996). Three trials were smaller (Boccalon 2000;
Daskalopoulos 2005; Ramacciotti 2004). Boccalon 2000 reported
results on 201 randomised participants (99 home and 102 hospi-
tal); Ramacciotti 2004 reported results on 104 home and 97 hos-
pital randomised participants; and in Daskalopoulos 2005, inves-
tigators randomised 108 participants (55 to home and 53 to hos-
pital). Bäckman 2004 evaluated and compared direct and indirect
medical costs during a three-month period for 131 randomised
participants (65 out-patient/home and 66 in-patient).
Bäckman 2004 did not report on any of the predefined outcomes
of this review other than costs; therefore we did not include this
study in any meta-analyses for these outcomes.
The three major trials (Chong 2005; Koopman 1996; Levine
1996) were similar in construction and results but differed in their
exclusion rates (see Characteristics of included studies; further dis-
cussed in Overall completeness and applicability of evidence). Of
the seven trials, only Boccalon 2000 and Bäckman 2004 used
LMWH in both treatment arms; the other five used LMWH in
home treatment arms and UFH in hospital treatment arms.
See Characteristics of included studies tables for further details of
the included studies.
Excluded studies
For this update, we excluded an additional five studies (Aujesky
2011; Hull 2009; Modesto-Alapont 2006; Otero 2010; Wilson
2003), for a total of 26 excluded studies (Aujesky 2011; Belcaro
1999; Blattler 1998; Buller 2004; Conner 1999; Fitzmaurice
2000; Frank 1998; Goldhaber 1998; Grau 1998; Grau 2001;
Green 1998;Hull 2000;Hull 2002;Hull 2009; Lindmarker 1996;
Miles 1998; Modesto-Alapont 2006; O’Shaugnessy 1998; Otero
2010; Pineo 2003; Rymes 2002; Ting 1998; Wells 1998; White
1989; Wilson 2003; Wimperis 1998).
Eight were uncontrolled studies (Conner 1999; Grau 1998; Green
1998; Lindmarker 1996; Miles 1998; O’Shaugnessy 1998; Ting
1998; Wimperis 1998), and two were retrospective studies (Grau
2001; Rymes 2002).We excluded the remaining 16 trials for a vari-
ety of reasons. We excluded two reported controlled trials because
participants were not actually randomised but instead were treated
according to their expressed therapeutic preferences (Blattler 1998;
Frank 1998). We excluded Wells 1998 because this study com-
pared patient-administered versus nurse-administered injections
rather than the location of treatment; Goldhaber 1998 because
participants randomised to treatment with LMWH in a home set-
ting were first required to be treated in hospital for several days;
Otero 2010 and Aujesky 2011 because these studies focussed on
PE - not DVT; Belcaro 1999 because this was primarily a trial of
formulations of heparin rather than a trial of home versus hospi-
tal treatment; Hull 2000 and Modesto-Alapont 2006 because in-
vestigators were concerned with prophylactic regimens including
LMWH for patients undergoing hip arthroplasty and for those
with VTE in obstructive pulmonary disease, respectively; Pineo
2003 and Hull 2002 because they investigated two protocols on
long-term effects of LMWH treatment - not location; and two
other trials because they did not include in-patient arms - Wilson
2003 compared anticoagulant clinics versus family clinics, and
Hull 2009 compared long-term subcutaneous tinzaparin versus
initial tinzaparin followed by long-term warfarin in the commu-
nity as opposed to home patients versus in-patients. White 1989
and Fitzmaurice 2000 were concerned with monitoring oral anti-
coagulation at home or in general practitioner (GP) surgery. Buller
2004 compared once-daily LMWHversus twice-daily doses in the
out-patient setting, and LMWH versus UFH in the out-patient
setting - not hospital versus home.
See also Characteristics of excluded studies.
Risk of bias in included studies
Figure 2 gives an overall view of our assessment of included
studies’ risk of bias, and Figure 3 shows the ’Risk of bias’ sum-
mary presented as percentages across all included studies. See also
Characteristics of included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
We considered the following methods of allocation concealment
adequate.
• Central allocation, including telephone randomisation.
• Use of sequentially numbered, opaque, sealed envelopes.
We deemed risk of bias as low if study authors described one of
these methods. We deemed risk of bias as unclear if researchers
described the trial as randomised but did not describe the method
used for allocation concealment.
All included trials were reported as randomised controlled trials
(RCTs). Random sequence generation was unclear in six studies
(Bäckman 2004; Boccalon 2000; Chong 2005; Koopman 1996;
Levine 1996; Ramacciotti 2004) but was adequate in a single trial
(Daskalopoulos 2005) as these investigators reported using a com-
puterised process.
Four trials adequately concealed allocation (Bäckman 2004;
Boccalon 2000; Koopman 1996; Levine 1996). Daskalopoulos
2005 did not report the method used, and Chong 2005 did not
report allocation concealment, so we rated both as having unclear
risk of bias. In the Ramacciotti 2004 study, researchers performed
randomisation by using blocks in an ’open manner’; we rated this
study as having high risk of bias.
Blinding
Blinding refers to whether participants and study personnel knew
which participants were treated in hospital, and which received
treatment at home. By the nature of this study, blinding was
never going to be easy to achieve. Five studies were open, non-
blinded studies (Chong 2005; Daskalopoulos 2005; Koopman
1996; Levine 1996; Ramacciotti 2004); we judged them to be at
high risk of bias. Participants in Bäckman 2004 were allowed to
change their assigned treatment or to leave the study after ran-
domisation, but we determined the risk of performance bias as low
for the outcomes of this study. Although Boccalon 2000 reported
no blinding of participants or personnel, both groups received the
same treatment. All participants received an oral anticoagulant for
the first three days. The review authors deemed that outcomes
were unlikely to have been affected by lack of blinding of partici-
pants or personnel, and so we judged this trial to be at low risk of
bias.
Four studies had independent outcome assessors, and we deemed
them to have low risk of detection bias (Chong 2005;
Daskalopoulos 2005; Koopman 1996; Levine 1996). Three stud-
ies did not report blinding of outcome assessors; therefore we
deemed these studies to be at high risk of detection bias (Bäckman
2004; Boccalon 2000; Ramacciotti 2004).
Incomplete outcome data
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Five of the seven included studies either reported on all participants
or adequately described their loss to follow-up; we rated them
as low risk (Bäckman 2004; Chong 2005; Daskalopoulos 2005;
Koopman 1996; Levine 1996). Ramacciotti 2004 and Boccalon
2000 had a high rate of attrition, and we rated them as high risk.
Selective reporting
We assessed a study for risk of selective outcome reporting accord-
ing to the following.
• The published report included all expected outcomes.
• Outcomes were reported systematically for all comparison
groups, based on prospectively collected data.
We deemed risk of bias to be low if both of these criteria were
met, unclear if these criteria were not met, and high if evidence
indicated that data had been collected on outcomes of interest but
were not reported in the study publication.
We did not find any indication suggesting that outcomes were
selectively reported in the included studies, so we rated all studies
as low risk.
Other potential sources of bias
We had no concerns regarding other potential sources of bias
for two studies (Boccalon 2000; Daskalopoulos 2005). For
Bäckman 2004, Chong 2005, Koopman 1996, Levine 1996, and
Ramacciotti 2004, information was insufficient for review authors
to judge whether there was potential for other bias; we rated these
as havingunclear risk, as each study included a large number of par-
ticipants in the LMWH/home treatment group who were treated
in hospital. Koopman 1996, Levine 1996, and Ramacciotti 2004
differed methodologically, as participants randomised to LMWH
were treated only at home, as determined by a clinician, but were
not specifically assigned to home treatment. We evaluated these
studies by performing sensitivity analysis to assess their impact on
evidence obtained through meta-analysis. We have discussed these
issues further in the sectionOverall completeness and applicability
of evidence.
Effects of interventions
See: Summary of findings for the main comparison Treatment
of DVT at home compared with treatment in hospital
We have presented a summary of the findings of this review in
Summary of findings for the main comparison, and a summary of
outcomes of included trials in Table 1.
Recurrent VTE (PE or recurrence of DVT)
Six studies reported on this outcome (Boccalon 2000; Chong
2005; Daskalopoulos 2005; Koopman 1996; Levine 1996;
Ramacciotti 2004). Outcome follow-up time ranged from three
months to one year. Pooled results showed differences in recur-
rence of VTE between home and hospital treatment, with home
treatment carrying less risk of recurrent VTE (RR 0.58, 95% CI
0.39 to 0.86; 1708 participants; 6 studies; I² = 0%; P = 0.007;
Analysis 1.1). We rated the evidence as low quality owing to risk
of bias and indirectness concerns.
Venous gangrene
Included studies reported no cases of venous gangrene.
Heparin complications including major and minor
bleeding
Six studies reported on this outcome (Boccalon 2000; Chong
2005; Daskalopoulos 2005; Koopman 1996; Levine 1996;
Ramacciotti 2004). Outcome follow-up ranged from 14 days to
one year.
Pooling of results on major bleeding revealed no clear differences
between home and hospital treatment groups (RR 0.67, 95% CI
0.33 to 1.36; 1708 participants; 6 studies; I² = 0%; P = 0.27;
Analysis 1.2). We rated the evidence as low quality owing to risk
of bias and indirectness concerns.
For the outcome of minor bleeding, data show no clear differences
between hospital and home treatment arms (RR 1.29, 95% CI
0.94 to 1.78; 1708 participants; 6 studies; I² = 0%; P = 0.11;
Analysis 1.3). We rated the evidence as low quality owing to risk
of bias and indirectness concerns.
Death
Six studies included reports on death, with follow-up ranging
from three months to one year (Boccalon 2000; Chong 2005;
Daskalopoulos 2005; Koopman 1996; Levine 1996; Ramacciotti
2004). Meta-analysis of trial results showed no clear differences
in numbers of deaths between home- and hospital-treated groups
(RR 0.69, 95% CI 0.44 to 1.09; 1708 participants; 6 studies; I² =
0%; P = 0.11; Analysis 1.4). We rated the evidence as low quality
owing to risk of bias and indirectness concerns.
Patient satisfaction and quality of life
Three studies included data on quality of life (QoL) (Bäckman
2004; Koopman 1996; Levine 1996). Bäckman 2004 assessed
QoL using the EuroQoL tool based on five dimensions (EQ-5D)
and found no differences between treatment groups in mean QoL
scores, nor in the proportion of participants showing improve-
ment in self-rated health state. QoLwas assessed immediately after
treatment and after three months. A substantial number of par-
ticipants randomised to in-patient care in this study chose out-
patient treatment, predominantly as a personal/social preference.
The Koopman 1996 trial measured QoL by using the Medical
Outcome Study Short Form 20 as a generic measure of physical
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and mental health, as well as an adapted version of the Rotter-
dam Symptom Checklist, which is specific to thrombosis; mea-
surements were taken at baseline, at end of treatment course, and
at 12 weeks and 24 weeks after treatment. At 24 weeks after treat-
ment, over 80% of both trial groups had completed the QoL
questionnaires. Overall, participants in both groups showed im-
provement in QoL; two out of six criteria (physical activity and
social functioning) showed an advantage for those in the LMWH
group at completion of initial treatment, but this difference was
not seen at 12 weeks or at 24 weeks after treatment. Levine 1996
reported on QoL seven days after treatment using the Medical
Outcomes Study Short Form 36, which reports on eight physical
and mental health domains. Only the social functioning domain
showed greater improvement among participants treated at home
compared with those given heparin treatment; data show no dif-
ferences between the two treatment groups in terms of the other
domains (O’Brien 1999). We could not carry out meta-analysis
for this outcome owing to heterogeneity in reporting of QoL and
the paucity of data reported by trial authors.
We rated the quality of evidence for this outcome as very low owing
to risk of bias, indirectness, and heterogeneity of measurement and
reporting.
Cost-effectiveness of treatment
Bäckman 2004, Boccalon 2000, Daskalopoulos 2005, and
Koopman 1996 all reported on cost-effectiveness of compared
treatments, but because of the way investigators presented data,
we could perform no meta-analysis for this outcome.
In Bäckman 2004, which reported on costs within three months
of treatment, 224 participants were eligible, 131 entered the trial,
and 124 completed the economic portion of the study. Total di-
rect costs were higher for participants in the in-patient strategy
group(i.e. Swedish Crown (SEK) 16,400 per participant (Euro
(EUR) 1899) compared with SEK 12,100 per participant (EUR
1405)) than for those in the out-patient (home) strategy group (P
< 0.0010).
Koopman 1996 followed participants for six months and used
trial results to compare cost of treatment calculations between
the two arms of the trial (van den Belt 1998). Data show a 64%
savings among those treated with LMWH as opposed to UFH,
largely owing to lower hospital costs. Trialists stated that this was a
conservative estimate of the potential reduction in costs. Similarly,
an evaluation of participants entered into the Levine 1996 trial
showed cost savings of 57% (O’Brien 1999); researchers followed
participants for three months. This latter figure is confirmed by
Boccalon 2000, which showed that the mean cost of in-patient
treatment over 10 days was over 55% higher than the mean cost
of out-patient treatment over the same time period. Similarly, in
Daskalopoulos 2005, which reported on 12 months of follow-up,
estimated costs slightly favoured the LMWH group because of the
significant cut in hospitalisation.
We rated the quality of evidence for this outcome as very low owing
to risk of bias, indirectness, and heterogeneity of measurement and
reporting.
Other outcomes of interest
None of the included trials considered the incidence of post-
thrombotic syndrome.
Mean hospital stay for participants without events such as bleeding
or (suspected) recurrences in Koopman 1996 was 8.1 days for the
hospital-treated ’control’ group, and 2.7 days for the home-treated
’treatment’ group. In the other large trial (Levine 1996), mean
hospital stay was 6.5 days for the hospital-treated control group
and 2.1 days for the home-treated group. Mean hospital stay in
Boccalon 2000 was 9.6 days for the hospital-treated group and
one day for the home-treated group. Ramacciotti 2004 reported
a mean hospital stay of three days for home-treated participants
and seven days for hospital-treated participants. Three studies did
not report duration of hospital stay (Bäckman 2004; Chong 2005;
Daskalopoulos 2005).
Thirty-six per cent of participants in Koopman 1996 were treated
entirely at home, 39% had a short hospital stay, and 25% were
entirely hospital treated. Fifty per cent of participants in Levine
1996 were treated entirely at home. In Daskalopoulos 2005, no
participant allocated to receive treatmentwith LMWHunderwent
any hospitalisation.
Seventy-seven per cent of participants in the home arm (LMWH
group) of the Chong 2005 trial were admitted to hospital. Twelve
per cent were released on the day of admission, 34% were kept for
one day, and 31% were kept for two or more nights. Ramacciotti
2004 reported hospitalisation for all hospital-treated participants
and for 64% of home-treated participants.
Heterogeneity, subgroup analysis, and sensitivity
analysis
We found heterogeneity in pooled effect estimates to be very low
and had no reason to further investigate. When we performed
sensitivity analysis, we found no difference in the effect when we
removed studies at high risk of bias (Ramacciotti 2004). No anal-
yses showed a majority weight by a single study, so we performed
no sensitivity analyses on these criteria. We performed sensitivity
analysis by evaluating the impact of the Koopman 1996, Levine
1996, and Ramacciotti 2004 trials given that participants ran-
domised to LMWH were treated only at home, as determined by
a clinician, but were not specifically assigned to home treatment.
This sensitivity analysis did not change the findings.
D I S C U S S I O N
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Summary of main results
This review presents low-quality evidence suggesting that patients
treated at home with low molecular weight heparin (LMWH) are
less likely to have recurrence of venous thromboembolism (VTE)
than those treated in an in-patient (hospital) setting. Data show
no clear differences in major or minor bleeding events nor in mor-
tality (all low-quality evidence), indicating that home treatment
is no worse for these outcomes when compared with in-patient
treatment.
Overall completeness and applicability of
evidence
Although the results of this review are promising, review authors
have several concerns about the applicability of the evidence. Our
primary concern is that a large number of participants in the home
treatment group were not treated solely at home. Also, there was
heterogeneity in the findings of the larger trials, making it difficult
to interpret and apply the results. Finally, a large number of eligi-
ble participants were excluded from trials before randomisation,
raising concerns about applicability.
Many of the participants randomised to home treatment with
LMWH were not actually treated fully at home but were hospi-
talised for some or all of the treatment period (see Table 2 for
details). Only 40% (in Bäckman 2004), 23% (in Chong 2005),
36% (in Koopman 1996), 48.5% (in Levine 1996), and 36% (in
Ramacciotti 2004) of those randomised to home treatment were
treated wholly at home, making trial results difficult to interpret.
In three trials, participants randomised to LMWH treatment, as
opposed to unfractionated heparin (UFH), could be treated at
home or in an in-patient setting at the discretion of clinicians or
investigators (Koopman 1996; Levine 1996; Ramacciotti 2004).
This creates the concern that data collected and reported in meta-
analyses may not directly speak to the question at hand. To address
these issues, we conducted extensive sensitivity analyses and found
no differences in our findings when we excluded the findings of
these studies. This issue is a problem not just with these few trials;
rather, it is an overall, possibly insurmountable problem, as deep
vein thrombosis (DVT) and its complications by their nature may
require in-patient treatment, even if a person is deemed accept-
able for home treatment. However, these trials have shown that
patients treated at home with LMWH are less likely to have re-
currence of VTE than their counterparts treated in hospital with
UFH or LMWH. Also, researchers found that participants pre-
ferred to have treatment at home. Concerns presented here most
likely contribute to dilution of review conclusions.
The three major randomised controlled trials (RCTs) compared
UFH in hospital versus LMWHat home (Chong 2005; Koopman
1996; Levine 1996). A more methodologically sound trial would
have compared LMWH in both groups, and this would have been
justified by the many trials and three meta-analyses showing that
LMWH is at least as effective as UFH (Erkens 2010; Leizorovicz
1994; Lensing 1995).
Another factor limiting review conclusions was the very high pre-
randomisation exclusion rate reported by several trials (Boccalon
2000; Koopman 1996; Levine 1996). Koopman 1996 reported ex-
clusion of 31% of eligible participants, and Levine 1996 reported
exclusion of 67%. Similarly, Boccalon 2000 (78%) and Bäckman
2004 (42%) reported high exclusion rates. Exclusion criteria were
very diffuse and could have been less strict. Daskalopoulos 2005
presented a contrasting low exclusion rate (7%). Ramacciotti 2004
and Chong 2005 did not report on prerandomisation exclusions,
except for three participants in the Chong 2005 trial, who were
enrolled but were not randomised because they did not receive
study treatment or did not provide treatment-related data.
Although we have included ’economic analysis’ as an outcome, a
comprehensive economic analysis is beyond the scope/expertise of
this review, so we have reported only limited data available from
the included studies.
Other issues that may affect applicability of our review include the
limited number of participants fromdeveloping countries, and the
fact that no high-quality RCTs have been published since 2005.
Trends in the treatment of individuals with VTE have been chang-
ing recently, with practitioners moving away from UFH and us-
ing more LMWHs along with the newer class of direct oral anti-
coagulants (DOACs). Treatment with LMWHs and DOACs has
been shown to be efficacious, with no increase in clinically rele-
vant complications (Robertson 2015; Robertson 2017). Although
UFH treatment is not going to disappear completely, practitioners
have been moving away from its usage and embracing LMWH
and DOACs owing to monitoring requirements and subsequent
costs of treatment with UFH. However, clinicians using DOACs
to treat patients with VTE have to reckon with their complexity,
involving appropriate dose selection for the relevant indication,
avoidance of drug-drug and drug-disease interactions, and con-
sideration of dose adjustments in specific clinical situations, such
as organ dysfunction (Finks 2016). This review did not evaluate
any studies that included the use of DOACs, such as rivaroxaban
or dabigatran, as no such studies met our inclusion criteria. We
therefore have presented limited evidence in this review for de-
tailed discussion of their use.
Quality of the evidence
Strengths of the evidence include the consistency and homogene-
ity of results from individual studies, as well as sufficient numbers
of participants and events included for each outcome. However,
we downgraded evidence generated in this review to low qual-
ity owing to concerns about risk of bias of individually included
studies, as well as indirectness of the data due to issues surround-
ing hospitalisation of participants randomised to home treatment,
as discussed in the previous section. A major concern associated
with risk of bias was selection bias: All seven included studies
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were at unclear or high risk for concerns with random sequence
generation or allocation concealment. Although minimising per-
formance bias would be very difficult owing to the open nature
of the treatment, making blinding of participants and personnel
nearly impossible, these issues could be addressed in other ways,
such as keeping treatment drugs consistent between interventions
or demonstrating more stringent control of detection bias. Risk
of bias concerns led us to downgrade the quality of evidence by
one level. These concerns reduce the robustness of findings. See
Summary of findings for the main comparison for further infor-
mation.
We conducted sensitivity analysis by evaluating the strength of
evidence in light of risk of bias issues, as well as concerns with
indirectness, and we found that findings did not change when we
removed studies with high risk of bias, or studies that may not
have directly contributed to the objectives of the review.
We did not investigate publication bias for the review because we
included fewer than 10 studies in the individual meta-analyses,
precluding robust results in the funnel plots used to investigate
publication bias.
Potential biases in the review process
During the review process, we adhered to all possible measures
to reduce potential biases, including conducting a comprehensive
search, performing double data extraction, and grading the evi-
dence.Wemade attempts to identify relevant studies and discussed
disagreements thoroughly.
Agreements and disagreements with other
studies or reviews
The results of uncontrolled trials encompass a considerable body
of evidence (Table 3), particularly in relation to practical ques-
tions (see Implications for research). An observational study that
included 334 participants concluded that community-based treat-
ment of individuals with thromboembolism was safe and effective
(Hyers 2007). Home treatment has also been investigated in spe-
cific pathological communities, including individuals with cancer,
and was found to be a suitable alternative to in-patient care (Ageno
2005).
In the UK, some local health authorities (Trusts) have published
the results of uncontrolled studies. Swindon Trust reported that
373 patients were referred to the programme, of whom 32% had
proven DVT and 37.5% were treated wholly or partially at home
(Green 1998). Chertsey Trust reported on 1093 referrals, of which
160 were proven to have a diagnosis of DVT. All but one (i.e. 159
patients) were home-treated (O’Shaugnessy 1998). Researchers
have reported no complications apart from two minor bleeds and
estimated savings to Chertsey Trust as £320,000 over 22 months.
In a combined presentation to the American Thoracic Society,
three trusts reported that they managed the care of 966 patients
with DVT, of whom only 10% were admitted to hospital (Miles
1998). In Norwich, 447 patients were referred over a six-month
period, scans were positive in 30%, and 20% of these were consid-
ered unsuitable for home treatment (Wimperis 1998). Thus, 105
were treated and five had to be readmitted - two with suspected
pulmonary embolism (PE) (negative scans), one with PE, one with
stroke, and one with an unrelated illness (Wimperis 1998).
A study from Melbourne presented 100 participants with proven
DVT (Ting 1998). Fifty-three participants had proximal throm-
bosis and were admitted for one day for investigation, includ-
ing lung scan: 16 scans were positive, although participants were
asymptomatic and the result did not affect their management at
home. The 47 participants with distal thrombosis were treated
entirely at home. The clot was initially extended in 13.2% of dis-
tal and 2.7% of proximal thromboses, but at follow-up scans at
six months, 60.7% of distal and 18.5% of proximal thromboses
had completely resolved. The only complications were six minor
bleeds. The numbers of participants referred but cleared of DVT,
and the numbers rejected by the protocol, were not mentioned. In
a Swedish study, 434 participants withDVTwere treated in hospi-
tal for three days before discharge home on treatment (Lindmarker
1996). Three participants had proven PE:Onemajor bleed and 16
minor ones occurred. Data show no deaths in the acute stage and
no extension of thromboses. In Grau 1998, 39 out of 71 partici-
pants with DVT were treated at home. Investigators reported no
instance of PE and only one minor bleed. These trials all reported
worthwhile cost savings. Only one uncontrolled study reported
on patient satisfaction (Conner 1999). Seventy-nine per cent of
participants were happy to be treated at home, 12% would have
preferred hospital treatment, and 9% had no preference.
Although not based on evidence fromRCTs, cost savings in favour
of home treatment have been shown when calculated. Hospital
Episode Statistics for the UK for 1993 show 17,000 admissions
for PE and 25,000 for DVT, with an average in-patient stay of
7.2 days (Griffin 1996). At an estimated cost of £200 per in-
patient day (1998 figures), hospitalisation costs alone amounted
to £60,480,000. If this could be reduced to, say, two days in 75%
of cases, at a cost of £12,600,000, a savings of £47,880,000 on
bed costs per annum would be realisable. Although it was not
in the remit of this review, it is worth noting that surveillance
of participants up to four years after randomisation to home or
hospital regimens revealed no differences between groups (Grau
2001).
Regarding the results of quality of life outcomes reported in
Bäckman 2004, Blattler 1998 (excluded from our review as it was
not an RCT) observed a similar preference in two-thirds of partic-
ipants, who challenged hospital confinement and stated that they
would not choose hospitalisation another time. The Blattler trial
also reported that its home treatment group was free of symptoms
a day earlier and returned to work a week earlier than the hospital
treatment group (Blattler 1998).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review presents low-quality evidence suggesting that patients
treated at home with low molecular weight heparin (LMWH) are
less likely to have recurrence of venous thromboembolism (VTE)
than those treated in hospital. Researchers have found no clear
differences in major or minor bleeding complications, nor in mor-
tality (low-quality evidence), indicating that treatment at home
with LMWH is not more harmful than treatment in an in-patient
setting with LMWH or unfractionated heparin (UFH). Despite
the limitations of reviewed trials, low-quality evidence suggests
that home treatment of patients with DVT is more effective than
standard hospital treatment.
Implications for research
It is unlikely that definitive evidence on the safety of home treat-
ment will be forthcoming for reasons addressed in the discus-
sion. This is underscored by the fact that during our search, we
identified no other high-quality randomised controlled trials pub-
lished after 2005. Also, treatment of individuals with thromboem-
bolism with LMWH is being incorporated into local health au-
thority guidelines that include at-home administration practices
(East Lancashire Health Economy 2015; Wong 2014). A larger
database of accumulated uncontrolled studies that can be com-
pared only with historical controls is needed. Anecdotal notes may
describe treatment failure but as these occurrences will be rare, it
is possible that they will not be published.
It has been suggested by Baron 1999 that patients should be allo-
cated on a triage basis: (1) standard in-patient regimen for those
with intercurrent illness or massive VTE; (2) partial home treat-
ment for those receiving the diagnosis in hospital but fit enough
for discharge; and (3) complete home treatment. The ideal trial
would compare LMWH only in each arm, would exclude 25%
or fewer participants from entry into the trial, and would present
trial results in three groups. These issues should be given further
examination.
Some practical issues remain to be resolved.
• Should the patient be admitted at all if suitable for home
treatment?
• Should LMWH be given on suspicion or only on
confirmation of the diagnosis?
• How would the treatment comparison be changed by use of
newer direct oral anticoagulants versus more traditional LMWH?
• Should exclusion criteria be relaxed to favour greater entry
to home treatment? For example, should a healthy pregnancy
preclude home treatment?
• Should a screening test such as D-dimer levels be used?
• Should the system be controlled by the traditional
physician’s team, or should specialist anticoagulant nurses be
trained? If so, will a lead clinician continue to accept overall
responsibility?
• How should local guidelines be developed that include
clinical prediction rules, biomarkers, and imaging that can be
used to tailor therapy to disease severity?
• How should community healthcare workers be trained to
administer treatment and monitor treatment progress?
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boccalon 2000
Methods Study design: randomised controlled trial
Exclusions post randomisation: One patient withdrew consent following randomisation,
7 withdrew owing to severe complications (3 DVT extensions, 4 major haemorrhages)
Losses to follow-up: 38 participants did not complete the 6-month follow-up (those
treated in hospital were twice as likely to withdraw)
Intention-to-treat analysis: not indicated
Participants Country: France
Setting: home or hospital
N: 204 randomised, 201 included (102 hospital, 99 home), representing 11.8% of those
eligible
Age: mean 63.8 ± 14.1 years, range 18 to 85 years
Sex: 113 male; 88 female
Inclusion criteria: confirmed diagnosis (by ultrasonography or venography) of proximal
DVT not more than 30 days before enrolment
Exclusion criteria: thrombus in the inferior vena cava, a floating thrombus, history of
DVT within the previous 6 months, DVT with symptomatic PE, a clinical condition
requiring hospitalisation, contraindication to anticoagulant treatment, pregnancy, hep-
arin treatment within the 48 hours preceding inclusion, home or hospital treatment
impossible for any reason, participant lived too far away from the trial centre, written
consent not given
Participants were also examined, although not necessarily excluded, for risk factors for
DVT, including previous thromboembolism, varicose veins, immobilisation, surgery,
trauma, cancer, use of oral contraceptives, known or inherited clotting disorders, other
comorbidities such as cardiovascular disease with right ventricular failure
Interventions Treatment: sc injection of LMWH (dalteparin sodium, enoxaparin sodium, or
nadroparin calcium, as chosen by the attending physician) at the recommended dose,
followed by anticoagulant for 6 months at home
Control: sc injection of LMWH (dalteparin sodium, enoxaparin sodium, or nadroparin
calcium, as chosen by the attending physician) at the recommended dose, followed by
anticoagulant for 6 months initially in hospital for 10 ± 2 days, then at home
Anticoagulants: oral VKA or fluindione, 20mg/d for the first 3 days, followed by regimen
to maintain INR between 2.0 and 3.0 for up to 6 months
Participants were also given compression stockings and were encouraged to return to
physical activity according to a schedule approved by general practitioner and nurse
Outcomes Primary: recurrent VTE, PE, major bleeding
Secondary: death, minor bleeding, economic analysis
Duration of follow-up: 6 months
Notes
Risk of bias
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Boccalon 2000 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Sealed envelopes were used.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although no blinding of participant or per-
sonnel was reported, both groups received
the same treatment. All participants re-
ceived an oral anticoagulant for the first 3
days. Outcome is unlikely to have been af-
fected by lack of blinding of participants or
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of outcome assessors was not re-
ported. Outcomes could have been influ-
enced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 38 participants did not complete the 6-
month follow-up (those treated in hospital
were twice as likely to withdraw)
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported.
Other bias Low risk No other potential bias was identified.
Bäckman 2004
Methods Study design: randomised multi-centre trial
Exclusions post randomisation: 7 patients excluded (5 randomised to in-patient treat-
ment refused to co-operate; 2 randomised to outpatient/home treatment had a drug
reaction and haematuria, respectively)
Losses to follow-up: none
Intention-to-treat analysis: yes
Participants Country: Sweden
Setting: in-patient or out-patient/home
N: 224 met inclusion criteria, 131 randomised (66 in-patient, 65 out-patient/home),
representing 58% of those eligible
Age: mean 66 (33 to 87) years, in-patient group; 67 (25 to 91) years, out-patient/home
group
Sex, male/female ratio: 34/34 in-patient group; 34/31 out-patient group
Inclusion criteria: acute symptomatic DVT confirmed by phlebography or ultrasound
in patients aged 18 years and older presenting at the emergency department
Exclusion criteria: not clearly stated
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Bäckman 2004 (Continued)
Interventions All participants were provided with intervention stockings. Both groups were treated
with LMWH administered sc once daily, adjusted for body weight, for at least 5 days
until prothrombin time was < 25% (INR > 2.0) for at least 1 day
Out-patient/home: Treatment included a daily visit to the out-patient department at a
primary care centre or a visit by the district nurse at the participant’s home, depending
on local circumstances or patient preference
In-patient: Participants were admitted to the ward.
Outcomes Direct medical and direct non-medical costs
Duration of follow-up: 3 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method used to generate the random
sequence was not described by trial authors
Allocation concealment (selection bias) Low risk Randomisation was performed centrally by
means of codes in envelopes in batches of
20. in accordance with Zelen 1979.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although participants were allowed to
change their assigned treatment or to leave
the study after randomisation, the review
authors determined that the risk of perfor-
mance bias was low
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not described; outcomes could have been
influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No data were missing.
Selective reporting (reporting bias) Low risk Prespecified outcomes were included.
Other bias Unclear risk Information was insufficient to reveal
whether other potential bias exists; only
40% of participants randomised to treat-
ment with LMWHwere actually treated at
home
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Chong 2005
Methods Study design: randomised parallel-group open study
Exclusions post randomisation: 63 (20%) were not included in the primary outcome
analysis
Losses to follow-up: 45 had no analysis at 24 weeks
Intention-to-treat analysis: yes
Participants Countries: Australia, New Zealand, Poland, South Africa
Setting: out-patient or hospital
N: 301 enrolled; 298 randomised (148 hospital, 150 home)
Age: 18+ years
Sex: 156 male, 142 female
Inclusion criteria: diagnosis of symptomatic lower extremity DVT (proximal or distal)
confirmed by contrast venography and/or ultrasonography, suitable for treatment in an
out-patient setting, prepared to self-administer daily sc injections, life expectancy > 6
months
Exclusion criteria: received therapeutic doses of heparin for more than 24 hours before
randomisation; clinically overt signs or symptoms of PE or evidence of PE on lung scan-
ning or pulmonary angiography; impending venous gangrene; previous HIT or another
hypersensitivity reaction to heparin; platelet count < 50 × 109/L; treatment with fibri-
nolytics or oral anticoagulants within the previous 5 days, or with other investigational
therapeutic agents within the previous 4 weeks; pregnancy or lactation; any clinically
significant medical condition other than DVT that would prevent discharge from hos-
pital
Interventions Treatment: once-daily sc injection of LMWH enoxaparin 1.5 mg/kg for a minimum of
5 days plus 10 mg of warfarin for 3 months with dose adjusted to achieve and maintain
INR above 2 and within range accepted by the investigator
Control: 5000 IU bolus of UFH for a minimum of 5 days, plus 10 mg warfarin started
on day 1 of treatment, for 3 months
Outcomes Primary: efficacy endpoint: incidence of symptomatic recurrent DVT
Safety endpoint: incidence of adverse effect, major or minor bleeding during the first 14
days
Secondary: incidence of PE, recurrent VTE
Duration of follow-up: 24 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Did not report use of adequate random se-
quence generation
Allocation concealment (selection bias) Unclear risk Did not report use of adequate conceal-
ment technique
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Chong 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were independent of the study
and investigators and were unaware of the
treatments that participants were receiving
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data were reported.
Selective reporting (reporting bias) Low risk All prespecified primary and secondary sa-
fety endpoints were reported
Other bias Unclear risk Information was insufficient to reveal
whether other potential bias exists; only
23% of participants randomised to treat-
ment with LMWH were actually treated
exclusively at home
Daskalopoulos 2005
Methods Study design: prospective randomised trial
Exclusions post randomisation: 6 patients withdrew consent following randomisation
Losses to follow-up: none
Intention-to-treat analysis: yes
Participants Country: Greece
Setting: out-patient or hospital
N: 108 randomised (55 LMWH, 53 UFH)
Age: 18 years and over, range 23 to 95, mean 58.6 years
Sex: 61 female, 41 male
Inclusion criteria: acute proximal DVT confirmed by colour duplex ultrasound scan not
more than 1 week from onset
Exclusion criteria: segmental DVT restricted to infrapopliteal deep veins or calf mus-
cles, as determined by duplex ultrasonography; symptomatic or clinically suspected PE;
history of recently diagnosed (within 12 months) DVT or PE; already receiving an-
ticoagulant therapy; bleeding tendency objectively confirmed; hypersensitivity to hep-
arin preparations or coumarin derivatives; uncontrolled hypertension; history of recently
diagnosed (less than 1 month) cerebrovascular accident, intracranial artery aneurysm,
infectious endocarditis, thrombocytopenia, active peptic ulcer, hepatic or renal failure,
history of asthma, recent spinal or epidural anaesthesia, or intraspinal paracentesis (less
than 5 days); recent surgery (less than 5 days); recently performed thrombolysis or receiv-
ing antiplatelet therapy; body weight less than 35 kg; pregnancy; illicit drug addiction;
altered mental status or impaired cognitive function with inability to comply with study
protocol
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Daskalopoulos 2005 (Continued)
Interventions Treatment: single sc injection of LMWH (tinzaparin sodium) at a weight-adjusted dose
(175 anti Xa IU/Kg) daily for 6 months
Control: iv bolus of 5000 IUUFH followed by iv infusion of UFH for 5 to 7 days. APTT
was measured after 4 hours of initiation of heparin administration and was repeated 6
hours thereafter to reach the therapeutic range (ratio: 1.5 to 2.5)
Oral anticoagulant was commenced on the third day following UFH therapy
Outcomes Primary: recanalisation of thrombosed veins, major events
Secondary: recurrent DVT, PE, major bleeding, minor bleeding, thrombocytopenia,
death
Duration of follow-up: 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done by means of a
computer schedule.
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study was open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Because a double-blind study was not feasi-
ble, all objective diagnostic tests were inter-
preted by specialists including Coagulation
Unit staff and Radiology staff whowere not
involved in the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data were reported.
Selective reporting (reporting bias) Low risk All predefined data endpoints were re-
ported.
Other bias Low risk No other potential bias was identified.
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Koopman 1996
Methods Study design: randomised controlled trial
Exclusions post randomisation: 2 (both withdrew consent, 1 from each group)
Losses to follow-up: 2 participants in each group were lost to follow-up at 12 weeks
Intention-to-treat analysis: yes
Participants Countries: The Netherlands, France, Italy, New Zealand, Australia
Setting: home or hospital
N: 400 randomised (202 LMWH, 198 UFH)
Age: 59 ± 17 years LMWH group, 62 ± 16 years UFH group
Sex: 203 male; 197 female
Inclusion criteria: acute symptomatic proximal DVT proven by venography or duplex
scan
Exclusion criteria: VTEwithin previous 2 years, suspected PE at presentation, geographic
inaccessibility, PTS, less than 18 years old, pregnancy, life expectancy less than 6 months,
previous treatment with heparin for longer than 24 hours
Interventions Treatment: twice-daily injections of LMWH (nadroparin calcium (Fraxiparine) at a dose
adjusted for participant’s weight) at home when appropriate; participants were instructed
by nurse on how to administer the injections themselves
Control: UFH (APTT adjusted dose, continuous iv infusion of 1250 IU per hour after
initial iv bolus of 5000 IU) in hospital
Duration: minimum 5 days, maximum 24 weeks
Oral anticoagulation: Warfarin commenced on day 1 and continued for 3 months, with
dose adjusted to attain INR 2.0 to 3.0
Outcomes Primary: symptomatic recurrent VTE
Secondary: major haemorrhage, death, quality of life comparisons, comparison of costs
(in-patient vs home)
Duration of follow-up: 6 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
was not reported.
Allocation concealment (selection bias) Low risk Allocation was performed by means of a
central 24-hour telephone service
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective testing was done blindly; docu-
mentation of all potential outcome events
was assessed by an independent adjudica-
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Koopman 1996 (Continued)
tion committee whose members were un-
aware of treatment assignments,
Incomplete outcome data (attrition bias)
All outcomes
Low risk All losses to follow-up were reported.
Selective reporting (reporting bias) Low risk All prespecified outcome measures were re-
ported.
Other bias Unclear risk Information was insufficient to determine
whether other potential bias exists; only
36% of participants randomised to treat-
ment with LMWHwere actually treated at
home
Levine 1996
Methods Study design: randomised controlled trial
Exclusions post randomisation: not stated
Losses to follow-up: none
Intention-to-treat analysis: not indicated, but analysis included all randomised partici-
pants
Participants Country: Canada
Setting: home or hospital
N: 500 randomised (247 LMWH, 253 UFH)
Age: mean 57 ± 17 years LMWH group, 59 ± 15 years UFH group
Sex: 301 male; 199 female
Inclusion criteria: acute proximal DVT proven on venography or duplex scan
Exclusion criteria: 2 or more previous episodes of DVT or PE; active bleeding; active
peptic ulcer; coagulation disorder; symptomatic PE; possibility of non-compliance; con-
traindications to LMWH; pregnancy; pretreatment with heparin for longer than 48
hours; inability to make follow-up visits due to geographical inaccessibility; presence of
known deficiency of antithrombin III, protein C, or protein S
Interventions Treatment: sc LMWH (enoxaparin 1 mg per kg body weight twice a day) primarily at
home
Control: UFH (APTT adjusted dose, continuous iv infusion of 20,000 IU after initial
iv bolus of 5000 IU) in hospital
Duration: minimum 5 days
Anticoagulants: Warfarin sodium was started on evening of day 2 and was continued for
at least 3 months. First dose of 10 mg was thereafter adjusted to maintain INR between
2.0 and 3.0
Outcomes Primary: symptomatic recurrent DVT or PE within 90 days of randomisation, major
bleeding, minor bleeding during study period and up to 48 hours after discontinuation
of study medication
Secondary: death, economic evaluation
Duration of follow-up: 3 months
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Levine 1996 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
was not reported.
Allocation concealment (selection bias) Low risk Treatment was assigned over the telephone
from a central site
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Testing and assessment for recurrent VTE
and bleeding were conducted by a commit-
tee unaware of treatment assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up were reported.
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported.
Other bias Unclear risk Information was insufficient to determine
whether other potential bias exists; only
48.5% of participants randomised to treat-
ment with LMWHwere actually treated at
home
Ramacciotti 2004
Methods Study design: randomised, open-label, multi-centre clinical trial
Exclusions post randomisation: not stated
Losses to follow-up: 53.6% at 6-month follow-up
Intention-to-treat analysis: not indicated but analysis included all randomised partici-
pants
Participants Country: Brazil
Setting: home or hospital
N: 201 randomised (104 enoxaparin, 97 UFH)
Age (years): mean 64 for home, 44 for hospitals
Sex: 69 male, 132 female
Inclusion criteria: age greater than or equal to 18 years, weight greater than or equal to
50 kg and < 110 kg, DVT symptoms for 10 days or longer, proximal lower limb DVT
(confirmed by duplex ultrasound or venography), ready access to local health service,
capable of using enoxaparin at home
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Ramacciotti 2004 (Continued)
Exclusion criteria: history of HIT or allergy to heparin; haemorrhagic diathesis; surgery
within 7 days; symptoms of PE, bilateral DVT; survival prognosis < 6 months; hepatic or
renal failure; received therapeutic doses of UFH or LMWH for 24 hours or longer in the
previous 48 hours; in hospital for another reason, with stay anticipated to last > 3 days;
initial platelet count < 100,000/mL; uncontrolled hypertension, with DBP greater than
or equal to 180; initial APTT > 1.3 times the normal value; INR > 1.5 at enrolment;
indication for thrombolysis or venous thrombectomy
Interventions Treatment: once-daily sc injection of LMWH enoxaparin at a dose of 1.5 mg/kg for 5
to 10 days, given at home or in hospital at the discretion of the healthcare provider
Control: iv bolus injection of 5000 IU of UFH followed by iv 500 IU/kg/d adjusted to
maintain an APTT of 1.5 to 2.5 times the normal value for 5 to 10 days in hospital
Anticoagulant: All participants received warfarin (with a targeted INR 2 to 3) for at least
3 months, starting at day 1 or 2 of treatment
Outcomes Primary: recurrent DVT, PE
Secondary: major and minor bleeding
Duration of follow-up: 6 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was by block 1:1 at each
centre to ensure balance in each treatment
arm, but method of random sequence gen-
eration was not reported
Allocation concealment (selection bias) High risk Each investigator received the randomisa-
tion scheme specifying the treatment allo-
cation for each participant enrolled in the
study. Thus the investigator could foresee
assignments and introduce selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 32.7% of enoxaparin and 46.4%
UFH participants were followed up after 6
months
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Ramacciotti 2004 (Continued)
Selective reporting (reporting bias) Low risk All prespecified safety endpoints were re-
ported.
Other bias Unclear risk Information was insufficient to determine
whether other potential bias exists; only
36% of participants randomised to treat-
ment with enoxaparin were actually treated
at home
APTT: activated partial thromboplastin time.
DBP; diastolic blood pressure.
DVT: deep vein thrombosis.
HIT: heparin-induced thrombocytopenia.
INR: international normalised ratio.
IU: international units.
iv: intravenous.
LMWH: low molecular weight heparin.
PE: pulmonary embolism.
PTS: post-thrombotic syndrome.
PTT: partial thromboplastin time.
sc: subcutaneous.
UFH: unfractionated heparin.
VKA: vitamin K antagonist.
VTE: venous thromboembolism.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aujesky 2011 Assessed effectiveness, safety, and efficacy of outpatient vs inpatient care for patients with acute PE - not
DVT
Belcaro 1999 Participants were randomised to different forms of heparin rather than to home or hospital treatment
Blattler 1998 Although this study is published as an RCT, the method described in the study report does not meet the
criteria for an RCT
Buller 2004 Compared once-daily LMWH vs twice-daily doses in the outpatient setting - not hospital vs home
Conner 1999 Uncontrolled trial
Fitzmaurice 2000 This study was concerned with monitoring of oral anticoagulation at home or in the GP surgery
Frank 1998 Although this study is published as an RCT, the method described in the study report does not meet the
criteria for an RCT
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(Continued)
Goldhaber 1998 Participants randomised to home care with LMWH were first required to be treated in hospital before
being discharged
Grau 1998 Not a randomised trial
Grau 2001 Retrospective study
Green 1998 Uncontrolled trial
Hull 2000 Trial concerned with prophylactic regimens using LMWH in patients undergoing hip arthroplasty
Hull 2002 Trial concerned with evaluating 2 long-term LMWH treatment protocols
Hull 2009 Not home vs in-patient care; both groups of participants treated outside hospital. Usual care was defined
as tinzaparin for 5 days or longer, followed by warfarin for 12 weeks
Lindmarker 1996 Uncontrolled trial
Miles 1998 Uncontrolled trial
Modesto-Alapont 2006 Investigated the use of LMWHadministered at home for prevention of VTE in patients with severe chronic
obstructive pulmonary disease
O’Shaugnessy 1998 Uncontrolled trial
Otero 2010 Focussed on PE - not DVT
Pineo 2003 Trial concerned with evaluating 2 long-term LMWH treatment protocols
Rymes 2002 Retrospective study
Ting 1998 Uncontrolled trial
Wells 1998 Controlled trial of nurse vs patient injection. Not related to admission or home treatment
White 1989 This trial was concerned with monitoring of oral anticoagulation at home or in the GP surgery
Wilson 2003 Study design not home vs in-patient, anticoagulant clinics vs family physician clinic. Intervention was
oral anticoagulant - not LMWH. Study population included anyone who required warfarin for at least 3
months - not specifically for DVT
Wimperis 1998 Uncontrolled trial
DVT: deep vein thrombosis.
LMWH: low molecular weight heparin.
PE: pulmonary embolism.
RCT: randomised controlled trial.
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VTE: venous thromboembolism.
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D A T A A N D A N A L Y S E S
Comparison 1. Treatment of DVT at home versus treatment in hospital
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence of VTE 6 1708 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.39, 0.86]
2 Major bleeding 6 1708 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.33, 1.36]
3 Minor bleeding 6 1708 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.94, 1.78]
4 Death 6 1708 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.44, 1.09]
Analysis 1.1. Comparison 1 Treatment of DVT at home versus treatment in hospital, Outcome 1
Recurrence of VTE.
Review: Home versus in-patient treatment for deep vein thrombosis
Comparison: 1 Treatment of DVT at home versus treatment in hospital
Outcome: 1 Recurrence of VTE
Study or subgroup Treatment (Home) Control (Hospital) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boccalon 2000 1/99 2/102 3.1 % 0.52 [ 0.05, 5.59 ]
Chong 2005 4/150 14/148 22.2 % 0.28 [ 0.09, 0.84 ]
Daskalopoulos 2005 3/55 6/53 9.6 % 0.48 [ 0.13, 1.83 ]
Koopman 1996 14/202 17/198 27.1 % 0.81 [ 0.41, 1.59 ]
Levine 1996 13/247 17/253 26.5 % 0.78 [ 0.39, 1.58 ]
Ramacciotti 2004 2/104 7/97 11.4 % 0.27 [ 0.06, 1.25 ]
Total (95% CI) 857 851 100.0 % 0.58 [ 0.39, 0.86 ]
Total events: 37 (Treatment (Home)), 63 (Control (Hospital))
Heterogeneity: Chi2 = 4.35, df = 5 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0069)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours home Favours hospital
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Analysis 1.2. Comparison 1 Treatment of DVT at home versus treatment in hospital, Outcome 2 Major
bleeding.
Review: Home versus in-patient treatment for deep vein thrombosis
Comparison: 1 Treatment of DVT at home versus treatment in hospital
Outcome: 2 Major bleeding
Study or subgroup Treatment (Home) Control (Hospital) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boccalon 2000 2/99 2/102 10.6 % 1.03 [ 0.15, 7.17 ]
Chong 2005 0/150 3/148 18.9 % 0.14 [ 0.01, 2.71 ]
Daskalopoulos 2005 2/55 4/53 21.9 % 0.48 [ 0.09, 2.52 ]
Koopman 1996 1/202 4/198 21.7 % 0.25 [ 0.03, 2.17 ]
Levine 1996 5/247 3/253 15.9 % 1.71 [ 0.41, 7.07 ]
Ramacciotti 2004 2/104 2/97 11.1 % 0.93 [ 0.13, 6.49 ]
Total (95% CI) 857 851 100.0 % 0.67 [ 0.33, 1.36 ]
Total events: 12 (Treatment (Home)), 18 (Control (Hospital))
Heterogeneity: Chi2 = 4.01, df = 5 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours home Favours hospital
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Analysis 1.3. Comparison 1 Treatment of DVT at home versus treatment in hospital, Outcome 3 Minor
bleeding.
Review: Home versus in-patient treatment for deep vein thrombosis
Comparison: 1 Treatment of DVT at home versus treatment in hospital
Outcome: 3 Minor bleeding
Study or subgroup Treatment (Home) Control (Hospital) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boccalon 2000 17/99 11/102 17.6 % 1.59 [ 0.79, 3.23 ]
Chong 2005 15/150 17/148 27.9 % 0.87 [ 0.45, 1.68 ]
Daskalopoulos 2005 3/55 3/53 5.0 % 0.96 [ 0.20, 4.56 ]
Koopman 1996 27/202 15/198 24.7 % 1.76 [ 0.97, 3.21 ]
Levine 1996 6/247 6/253 9.7 % 1.02 [ 0.33, 3.13 ]
Ramacciotti 2004 12/104 9/97 15.2 % 1.24 [ 0.55, 2.82 ]
Total (95% CI) 857 851 100.0 % 1.29 [ 0.94, 1.78 ]
Total events: 80 (Treatment (Home)), 61 (Control (Hospital))
Heterogeneity: Chi2 = 3.07, df = 5 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours home Favours hospital
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Analysis 1.4. Comparison 1 Treatment of DVT at home versus treatment in hospital, Outcome 4 Death.
Review: Home versus in-patient treatment for deep vein thrombosis
Comparison: 1 Treatment of DVT at home versus treatment in hospital
Outcome: 4 Death
Study or subgroup Treatment (Home) Control (Hospital) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boccalon 2000 0/99 2/102 5.8 % 0.21 [ 0.01, 4.24 ]
Chong 2005 2/150 2/148 4.7 % 0.99 [ 0.14, 6.91 ]
Daskalopoulos 2005 2/55 5/53 12.0 % 0.39 [ 0.08, 1.90 ]
Koopman 1996 14/202 16/198 38.0 % 0.86 [ 0.43, 1.71 ]
Levine 1996 11/247 17/253 39.5 % 0.66 [ 0.32, 1.39 ]
Ramacciotti 2004 0/104 0/97 Not estimable
Total (95% CI) 857 851 100.0 % 0.69 [ 0.44, 1.09 ]
Total events: 29 (Treatment (Home)), 42 (Control (Hospital))
Heterogeneity: Chi2 = 1.65, df = 4 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours home Favours hospital
A D D I T I O N A L T A B L E S
Table 1. Summary of outcomes
Study Setting Number
of partic-
ipants en-
tered
Heparin
type
Mean hos-
pital stay
(days)
Recur-
rence of
VTE (%)
Ma-
jor bleed-
ing (%)
Mi-
nor bleed-
ing (%)
Death (%) Mean total
di-
rect costs
per partic-
ipant
Bäckman
2004
Hospital 65 LMWH 3.6 - - - - SEK 16,
400
Home 66 LMWH 1.6 - - - - SEK 12,
100
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Table 1. Summary of outcomes (Continued)
Boccalon
2000
Hospital 102 LMWH 9.5 2.0 2.0 10.8 2.0 Fr 20,932
Home 99 LMWH 1.4 1.0 2.0 17.2 0 Fr 9230
Chong
2005
Hospital 148 UFH - 9.5 2.0 11.5 1.4 -
Home 150 LMWH - 2.7 0 10.0 1.3 -
Daskalopou-
los
2005
Hospital 53 UFH - 11.3 7.5 5.7 3.8 -
Home 55 LMWH - 9.1 3.6 5.5 1.8 -
Koopman
1996
Hospital 198 UFH 8.1 8.6 2.0 7.6 8.1 -
Home 202 LMWH 2.7 6.9 0.5 13.4 6.9 -
Levine
1996
Hospital 253 UFH 6.5 6.7 1.2 2.3 6.7 -
Home 247 LMWH 2.1 5.3 2.0 2.4 4.5 -
Ramac-
ciotti
2004
Hospital 97 LMWH 3 2 2 12 - -
Home 104 UFH 7 7 3 9 - -
LMWH: low molecular weight heparin.
UFH: unfractionated heparin.
VTE: venous thromboembolism.
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Table 2. Percentage of participants treated at home
Participants Bäckman
2004
Boccalon
2000
Chong 2005 Daskalopou-
los
2005
Koopman
1996
Levine 1996 Ramacciotti
2004
Randomised
(N)
131 201 298 108 400 500 201
Excluded after
randomisa-
tion (%)
5.3 18.9 20 5.5 0 0 0
Randomised
to home/
LMWH treat-
ment andwere
ac-
tually treated
at home (not
hospitalised)
(%)
40a 74 23b 100c 36 48.5 36
aBäckman 2004 reported that 40% of those randomised to home treatment remained at home, and 40% were hospitalised; it is unclear
what happened with the remaining 20%; 36 randomised participants changed treatment, 26 of whom changed from hospital to
home, and 10 from home to hospital.
bChong 2005 reported that 23% of those randomised to home treatment were exclusively treated at home, 12% were hospitalised and
discharged within a day, and 35% were hospitalised for one night, 23% for two nights, and 8% for three or more nights.
cDaskalopoulos 2005 initially reported: “Patients allocated to receive treatment with LMWH underwent no hospitalizations at all”,
but later in the text trial authors state: “The number of major events requiring hospitalization was significantly lower in the LMWH
group”, making it unclear whether those randomised to LMWH were exclusively treated at home.
LMWH: low molecular weight heparin.
Table 3. Uncontrolled trials - participant demographics
Trial author Referrals Positive scans % home treated
Grau 1998 - 71 55.0
Green 1998 373 119 37.5
Lindmarker 1996 - 434a 100.0
Miles 1998 - 966 90.0
O’Shaugnessy 1998 1093 160 99.9
Ting 1998 - 53b 100.0
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Table 3. Uncontrolled trials - participant demographics (Continued)
Wimperis 1998 447 134 80.0
Total 1451
a3 days’ hospital treatment before discharge.
bExcluding distal thrombosis.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MESH DESCRIPTOR Thrombosis 1261
#2 MESH DESCRIPTOR Thromboembolism 919
#3 MESH DESCRIPTOR Venous Thromboembolism 257
#4 MESHDESCRIPTOR Venous Thrombosis EXPLODE ALL
TREES
2036
#5 (thrombus* or thrombopro* or thrombotic* or thrombolic*
or thromboemboli* or thrombos* or embol*):TI,AB,KY
18960
#6 MESH DESCRIPTOR Pulmonary Embolism EXPLODE
ALL TREES
746
#7 (PE or DVT or VTE):TI,AB,KY 4979
#8 ((vein* or ven*) near thromb*):TI,AB,KY 6702
#9 (blood near3 clot*):TI,AB,KY 2963
#10 (pulmonary near3 clot*):TI,AB,KY 5
#11 (lung near3 clot*):TI,AB,KY 4
#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11
24595
#13 MESH DESCRIPTOR Outpatients 983
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(Continued)
#14 MESH DESCRIPTOR Inpatients 703
#15 MESHDESCRIPTORPatientCare EXPLODEALLTREES 48022
#16 MESH DESCRIPTOR Ambulatory Care 2843
#17 MESH DESCRIPTOR Home Nursing 253
#18 MESH DESCRIPTOR Hospitalization EXPLODE ALL
TREES
10891
#19 MESH DESCRIPTOR Outpatient Clinics, Hospital 541
#20 in-patient:TI,AB,KY 4947
#21 inpatient:TI,AB,KY 5166
#22 hospitali*:TI,AB,KY 25539
#23 bed-ridden:TI,AB,KY 20
#24 bedridden:TI,AB,KY 107
#25 home:TI,AB,KY 19783
#26 out-patient:TI,AB,KY 1246
#27 outpatient:TI,AB,KY 15589
#28 ambulatory*:TI,AB,KY 14873
#29 domicil*:TI,AB,KY 383
#30 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR
#27 OR #28 OR #29
108891
#31 #12 AND #30 3043
43Home versus in-patient treatment for deep vein thrombosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. Trials registries searches
Clinicaltrials.gov
44 studies found for: embolism AND home
WHO
809 records for 256 trials for: embolism AND home
ISRCTN
18 records for: embolism AND home
F E E D B A C K
Anticoagulant feedback, 14 February 2011
Summary
Feedback received on this review, and other reviews and protocols on anticoagulants, is available on the Cochrane Editorial Unit website
at http://www.editorial-unit.cochrane.org/anticoagulants-feedback.
WH A T ’ S N E W
Last assessed as up-to-date: 16 March 2017.
Date Event Description
29 May 2017 New search has been performed Searches rerun. One new study included and five new
studies excluded
29 May 2017 New citation required but conclusions have not changed Searches rerun. One new study included and five new
studies excluded. Review text updated to incorporate up-
dated Cochrane requirements. New headings added, in-
cluded studies assessed for risk of bias, GRADE ratings
generated, and ’Summary of findings’ table populated.
Conclusions not changed
H I S T O R Y
Protocol first published: Issue 2, 2000
Review first published: Issue 2, 2001
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Date Event Description
14 February 2011 Amended Link to anticoagulant feedback added
13 May 2008 Amended Converted to new review format
9 November 2007 New search has been performed No new trials found. One additional secondary ref-
erence added to Ramacciotti 2004 (included study).
Conclusions not changed
22 May 2007 New citation required but conclusions have not
changed
New team of review authors. Two new included tri-
als and six new excluded trials. Overall conclusions
strengthened with further evidence
27 May 2004 New search has been performed No new trials found. Review updated as it stands
C O N T R I B U T I O N S O F A U T H O R S
RO: independently selected articles; assessed studies for inclusion; assessed the methodological quality of selected trials; extracted data;
and contributed to discussion of the final report of the review.
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of the method previously used for Jadad 1996. We added a ’Summary of findings’ table and assessed the quality of evidence according
to the GRADE method (Atkins 2004).
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